Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey.

  • Read more about Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey.

Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH).

  • Read more about Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH).

Factors influencing survival in sphingosine phosphate lyase insufficiency syndrome: a retrospective cross-sectional natural history study of 76 patients.

  • Read more about Factors influencing survival in sphingosine phosphate lyase insufficiency syndrome: a retrospective cross-sectional natural history study of 76 patients.

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.

  • Read more about Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.

Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study.

  • Read more about Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study.

Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States.

  • Read more about Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States.

Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients.

  • Read more about Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients.

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).

  • Read more about Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).

Assessing the impact of the five senses on quality of life in mucopolysaccharidoses.

  • Read more about Assessing the impact of the five senses on quality of life in mucopolysaccharidoses.

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

  • Read more about Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Pagination

  • Page 1
  • Next page ››
Subscribe to Orphanet journal of rare diseases

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List